The clinical application of COX-2 inhibitors may strengthen the sensitivity of renal cell carcinoma to immunotherapy

Medical Hypotheses

Volumn 71, Issue 4, 2008, Pages 527-529

  Li, Jinfeng ^a   Wang, Guomin ^a   Chu, Yiwei ^a   Rong, Ruiming ^a   Zhu, Tongyu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2;

ARTICLE; CANCER IMMUNOTHERAPY; ENZYME INHIBITION; KIDNEY CARCINOMA; LYMPHOCYTE TRANSFORMATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

CARCINOMA, RENAL CELL; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MODELS, THEORETICAL;

EID: 50449085848     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.06.010     Document Type: Article

References (8)

1. Amato R.J. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16 (2005) 7-15
2. Beyer M., and Schultze J.L. Regulatory T cells in cancer. Blood 108 (2006) 804-811
3. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
4. Griffiths R.W., Elkord E., Gilham D.E., et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immun 56 (2007) 1743-1753
5. Dannull J., Su Z., Rizzieri D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3633
6. + regulatory T cell-depleted mice. Cancer Res 65 (2005) 8471-8478
7. Tuna B., Yorukoglu K., Gurel D., Mungan U., and Kirkali Z. Significance of COX-2 expression in human renal cell carcinoma. Urology 64 (2004) 1116-1120
8. + T Regulatory cell activities in lung cancer. Cancer Res 65 (2005) 5211-5220